Recent News

• 04.25.2025 - AbbVie Reports First-Quarter 2025 Financial Results
• 04.24.2025 - AbbVie Submits Biologics License Application to U.S. FDA for TrenibotulinumtoxinE (TrenibotE) for the Treatment of Glabellar Lines
• 04.08.2025 - AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
• 03.31.2025 - AbbVie to Host First-Quarter 2025 Earnings Conference Call
• 03.26.2025 - AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
• 03.24.2025 - Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025
• 03.15.2025 - ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
• 03.04.2025 - AbbVie to Present at the Leerink Partners Global Healthcare Conference
• 03.03.2025 - AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
• 02.28.2025 - AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis

Recent Filings